Invicta Diagnostic Ltd
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
- Market Cap ₹ 88.0 Cr.
- Current Price ₹ 70.0
- High / Low ₹ 105 / 58.1
- Stock P/E 17.9
- Book Value ₹ 39.7
- Dividend Yield 0.00 %
- ROCE 20.3 %
- ROE 14.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 7.46 | 7.99 | 30.10 | 32.35 | |
| 4.22 | 4.59 | 21.09 | 22.58 | |
| Operating Profit | 3.24 | 3.40 | 9.01 | 9.77 |
| OPM % | 43.43% | 42.55% | 29.93% | 30.20% |
| 0.00 | 0.35 | 0.57 | 0.69 | |
| Interest | 0.02 | 0.08 | 0.23 | 0.20 |
| Depreciation | 0.95 | 0.98 | 2.49 | 3.25 |
| Profit before tax | 2.27 | 2.69 | 6.86 | 7.01 |
| Tax % | 22.91% | 0.00% | 31.63% | 30.39% |
| 1.76 | 2.69 | 4.69 | 4.88 | |
| EPS in Rs | 204.56 | 5.57 | 3.91 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 41% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.13 | 8.42 | 12.57 | |
| Reserves | 12.05 | 8.41 | 37.35 | |
| 1.87 | 1.67 | 3.67 | ||
| 1.79 | 2.75 | 6.66 | ||
| Total Liabilities | 15.84 | 21.25 | 60.25 | |
| 11.78 | 9.62 | 19.20 | ||
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 0.00 | 4.33 | 6.20 | |
| 4.06 | 7.30 | 34.85 | ||
| Total Assets | 15.84 | 21.25 | 60.25 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 4.21 | 6.47 | 2.93 | ||
| -10.01 | -5.23 | -13.67 | ||
| 7.14 | -0.42 | 30.79 | ||
| Net Cash Flow | 1.34 | 0.83 | 20.05 | |
| Free Cash Flow | -8.56 | 6.15 | -9.93 | |
| CFO/OP | 124% | 72% | 40% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 37.46 | 17.70 | 6.43 | |
| Inventory Days | 296.56 | 83.33 | 78.88 | |
| Days Payable | 1,102.60 | 70.00 | 254.03 | |
| Cash Conversion Cycle | -768.58 | 31.04 | -168.72 | |
| Working Capital Days | 5.94 | 21.58 | 55.74 | |
| ROCE % | 46.45% | 20.28% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Average revenue per test (ARPT) INR |
|
||
| Individual consumer business revenue share % |
|||
| Number of diagnostic centres centres |
|||
| Number of patients served patients |
|||
| Number of tests per patient visit tests per patient |
|||
| Number of tests performed tests |
|||
| Radiology revenue share % |
|||
Extracted by Screener AI
Documents
Announcements
-
Press Release
1 July 2026 - Pune diagnostic centre started commercial operations on 30 June 2026; network now has 10 centres and 1 lab.
-
Commencement of commercial production/operations
30 June 2026 - Pune diagnostic centre of subsidiary Porteus Medical LLP began operations on 30 June 2026; ₹416 lakh investment.
-
Acquisition
12 June 2026 - Porteus Pathogenius LLP step-down subsidiary incorporated; initial LLP agreement executed on 12 June 2026.
-
Acquisition
1 June 2026 - Porteus Medical LLP formed Porteus Pathogenius LLP as step-down subsidiary with Rs 51,000 for 51% stake.
-
Statement of deviation(s) or variation(s) under Reg. 32
29 May 2026 - Invicta Diagnostic reported no deviation in IPO fund use for half year and year ended March 31, 2026.
Concalls
-
May 2026Transcript PPT
Business Overview:[1]
IDL is a diagnostic services company operating across the MMR Region under the consumer brand P C Diagnostics, offering integrated radiology and pathology services with a focus on MRI, CT, and PET-CT. The company is supported by a structured hub-and-spoke network.